PROCEPT BioRobotics (NASDAQ:PRCT) Director Antal Rohit Desai Purchases 167,246 Shares

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Director Antal Rohit Desai acquired 167,246 shares of the stock in a transaction dated Thursday, March 5th. The stock was acquired at an average price of $25.58 per share, for a total transaction of $4,278,152.68. Following the completion of the acquisition, the director directly owned 167,246 shares of the company’s stock, valued at $4,278,152.68. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Antal Rohit Desai also recently made the following trade(s):

• On Monday, March 9th, Antal Rohit Desai purchased 98,699 shares of PROCEPT BioRobotics stock. The stock was acquired at an average price of $24.55 per share, for a total transaction of $2,423,060.45.
• On Friday, March 6th, Antal Rohit Desai bought 160,317 shares of PROCEPT BioRobotics stock. The stock was bought at an average cost of $23.59 per share, for a total transaction of $3,781,878.03.

PROCEPT BioRobotics Stock Up 4.3%

PRCT stock traded up $1.04 during mid-day trading on Monday, reaching $25.26. The company had a trading volume of 2,163,428 shares, compared to its average volume of 1,640,943. PROCEPT BioRobotics Corporation has a 52 week low of $19.35 and a 52 week high of $66.85. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -14.77 and a beta of 1.03. The company has a debt-to-equity ratio of 0.14, a current ratio of 6.85 and a quick ratio of 5.77. The stock has a 50 day simple moving average of $29.11 and a two-hundred day simple moving average of $32.83.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its earnings results on Wednesday, February 25th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.21). PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 25.13%. The firm had revenue of $76.38 million during the quarter, compared to the consensus estimate of $93.70 million. During the same period in the prior year, the business posted ($0.35) earnings per share. PROCEPT BioRobotics’s quarterly revenue was up 11.9% compared to the same quarter last year. As a group, equities analysts predict that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of PROCEPT BioRobotics

Several institutional investors have recently added to or reduced their stakes in PRCT. Prosight Management LP grew its stake in PROCEPT BioRobotics by 1,692.4% during the fourth quarter. Prosight Management LP now owns 1,380,000 shares of the company’s stock worth $43,415,000 after buying an additional 1,303,009 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of PROCEPT BioRobotics by 58.6% during the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock worth $122,052,000 after acquiring an additional 1,262,928 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in shares of PROCEPT BioRobotics by 59.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after acquiring an additional 1,218,815 shares during the period. Chicago Capital LLC boosted its position in shares of PROCEPT BioRobotics by 175.7% during the 3rd quarter. Chicago Capital LLC now owns 1,568,845 shares of the company’s stock worth $55,992,000 after acquiring an additional 999,873 shares in the last quarter. Finally, Westfield Capital Management Co. LP increased its stake in PROCEPT BioRobotics by 113.5% in the second quarter. Westfield Capital Management Co. LP now owns 1,598,349 shares of the company’s stock valued at $92,065,000 after acquiring an additional 849,792 shares during the last quarter. 89.46% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

PRCT has been the subject of a number of research analyst reports. Leerink Partners reduced their price target on PROCEPT BioRobotics from $55.00 to $30.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Truist Financial reduced their target price on PROCEPT BioRobotics from $47.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Morgan Stanley dropped their price target on PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 2nd. TD Cowen reduced their price objective on shares of PROCEPT BioRobotics from $50.00 to $34.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Thursday, January 22nd. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $40.82.

Trending Headlines about PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Director Antal Rohit Desai completed a series of large open‑market purchases March 5–9, increasing his stake to 426,262 shares; the three Form 4 filings show roughly $10.5M of insider buying over those days — a strong bullish signal that executives view the stock as undervalued. Insider Purchase Filings
• Positive Sentiment: Research coverage was initiated at Robert W. Baird, which can increase visibility and trading interest (Baird’s note content/rating not included in the filing). Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Two senior executives (EVPs Kevin Waters and Alaleh Nouri) sold small stakes (6,721 and 6,892 shares respectively on March 6) for a combined ~13.6k shares (~$322k), likely personal liquidity rather than a company signal given the scale relative to the director’s purchases. Kevin Waters Sale Filing Alaleh Nouri Sale Filing
• Negative Sentiment: Two law firms (Levi & Korsinsky and Schall) announced securities‑fraud investigations related to PROCEPT’s prior guidance and statements (citing prior revenue targets and handpiece pricing comments). Such investigations raise the risk of litigation, distraction and potential disclosures or restatements — a clear negative catalyst for sentiment. Levi & Korsinsky Investigation Notice Schall Law Firm Investigation Notice

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.